- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT06807281
Dlouhodobá studie léku zvaná abrocitinib u dětí ve věku 2 let a starších s mírným až těžkým ekzémem
Fáze 3, multicentrická, dlouhodobá a otevřená studie štítků hodnotící bezpečnost a účinnost abrocitinibu, s nebo bez lokálních léků podávaných dětským účastníkům ve věku 2 let a starší s mírnou až těžkou atopickou atopickou dermatitidou
This 24-month study will assess the long-term safety and efficacy of liquid abrocitinib oral suspension with or without topical medications in children 2 years of age or older with moderate-to-severe atopic dermatitis. The study will enroll two groups: participants who have completed other abrocitinib studies and participants who have never participated in abrocitinib studies.
Přehled studie
Detailní popis
Phase 3, open-label study to assess the long-term safety and efficacy of liquid abrocitinib oral suspension with or without topical medications in children ≥2 years of age with moderate-to-severe atopic dermatitis (AD). This study will enroll participants in two cohorts: an extension cohort of participants who previously completed prior abrocitinib studies, and a de novo cohort of participants (6 to <12 years of age) who have not participated in previous abrocitinib studies. Study duration will be up to 2 years (or commercial availability, whichever occurs earlier). The study will enroll a maximum of approximately 500 participants with moderate-to-severe Atopic Dermatitis from study sites globally (extension cohort will enroll up to 320 participants; de novo cohort will enroll approximately 180 participants). All participants will receive the study intervention abrocitinib oral suspension.
Typ studie
Zápis (Odhadovaný)
Fáze
- Fáze 3
Kontakty a umístění
Studijní kontakt
- Jméno: Pfizer CT.gov Call Center
- Telefonní číslo: 1-800-718-1021
- E-mail: ClinicalTrials.gov_Inquiries@pfizer.com
Studijní místa
-
-
-
Fukuoka, Japonsko, 811-1394
- Nábor
- Fukuoka National Hospital
-
Fukuoka, Japonsko, 819-0042
- Nábor
- Saruta Dermatology Clinic
-
-
Kanagawa
-
Yokohama, Kanagawa, Japonsko, 220-6208
- Nábor
- Queen's square Medical Facilities Queen's square Dermatology and Allergology
-
-
Osaka
-
Sakai, Osaka, Japonsko, 593-8324
- Nábor
- Dermatology and Ophthalmology Kume Clinic
-
-
Tokyo
-
Setagaya-ku, Tokyo, Japonsko, 157-0066
- Nábor
- Sasamoto Children's Clinic
-
-
-
-
Baranya
-
Pécs, Baranya, Maďarsko, 7632
- Nábor
- Pécsi Tudományegyetem Klinikai Központ
-
-
Bekes County
-
Békéscsaba, Bekes County, Maďarsko, 5600
- Nábor
- Trial Pharma Kft.
-
-
Csongrád-csanád
-
Szeged, Csongrád-csanád, Maďarsko, 6720
- Zatím nenabíráme
- University of Szeged
-
-
Pest County
-
Budapest, Pest County, Maďarsko, 1033
- Nábor
- Clinexpert Kft.
-
-
-
-
-
Chihuahua City, Mexiko, 31238
- Zatím nenabíráme
- Servicios Hospitalarios de Mexico S.A. DE C.V.
-
-
Mexico City
-
Mexico City, Mexico City, Mexiko, 06720
- Zatím nenabíráme
- Hospital Infantil de Mexico Federico Gomez
-
-
Nuevo León
-
Monterrey, Nuevo León, Mexiko, 64718
- Zatím nenabíráme
- Eukarya Pharmasite S.C.
-
-
Veracruz Ignacio de LA Llave
-
Veracruz, Veracruz Ignacio de LA Llave, Mexiko, 91900
- Zatím nenabíráme
- Arké SMO S.A de C.V
-
-
-
-
Lesser Poland Voivodeship
-
Krakow, Lesser Poland Voivodeship, Polsko, 30-002
- Nábor
- Specjalistyczny Gabinet Dermatologiczny Aplikacyjno-Badawczy, Marek Brzewski, Paweł Brzewski spółka cywilna
-
-
Lublin Voivodeship
-
Lublin, Lublin Voivodeship, Polsko, 20-573
- Nábor
- LUXDERM Specjalistyczny Gabinet Dermatologiczny prof. dr hab. n. med. Dorota Krasowska
-
-
Masovian Voivodeship
-
Warsaw, Masovian Voivodeship, Polsko, 02-625
- Nábor
- Centrum Medyczne Evimed
-
-
Silesian Voivodeship
-
Chorzów, Silesian Voivodeship, Polsko, 41-500
- Nábor
- DERMAPOLIS Medical Dermatology Center dr n. med. Edyta Gebska
-
-
Łódź Voivodeship
-
Lodz, Łódź Voivodeship, Polsko, 90-436
- Nábor
- Dermoklinika - Centrum Medyczne spółka cywilna M. Kierstan, J. Narbutt, A. Lesiak
-
-
Świętokrzyskie Voivodeship
-
Ostrowiec Świętokrzyski, Świętokrzyskie Voivodeship, Polsko, 27-400
- Nábor
- Dermedic Jacek Zdybski
-
-
-
-
Alabama
-
Birmingham, Alabama, Spojené státy, 35244
- Nábor
- Cahaba Dermatology & Skin Health Center
-
-
Arkansas
-
North Little Rock, Arkansas, Spojené státy, 72117
- Nábor
- Arkansas Research Trials
-
-
California
-
San Diego, California, Spojené státy, 92123
- Nábor
- Investigational Drug Service - Rady Childrens Hospital-San Diego
-
San Diego, California, Spojené státy, 92123
- Nábor
- University of California, San Diego/ Rady Children's Hospital - San Diego
-
-
Florida
-
Jacksonville, Florida, Spojené státy, 32256
- Nábor
- Solutions Through Advanced Research
-
-
Idaho
-
Meridian, Idaho, Spojené státy, 83646
- Nábor
- Ada West Research - Meridian
-
-
Indiana
-
Indianapolis, Indiana, Spojené státy, 46250
- Nábor
- Dawes Fretzin Clinical Research Group, LLC
-
-
Missouri
-
St Louis, Missouri, Spojené státy, 63104
- Nábor
- Saint Louis University
-
-
South Carolina
-
Charleston, South Carolina, Spojené státy, 29425
- Nábor
- Medical University of South Carolina - South Carolina Translational Research Nexus Clinic
-
Greenville, South Carolina, Spojené státy, 29607
- Nábor
- Tribe Clinical Research, LLC
-
-
Texas
-
San Antonio, Texas, Spojené státy, 78235
- Nábor
- Texas Dermatology and Laser Specialists
-
-
-
-
-
Shanghai, Čína, 200062
- Nábor
- Shanghai Children's Hospital
-
Shanghai, Čína, 200092
- Nábor
- Xinhua Hospital Affiliated to Shanghai JiaoTong University School of Medicine
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, Čína, 100045
- Nábor
- Beijing Children's hospital, Capital Medical University
-
-
Guangdong
-
Shenzhen, Guangdong, Čína, 518026
- Nábor
- Shenzhen Children's Hospital
-
-
Hunan
-
Changsha, Hunan, Čína, 410007
- Nábor
- Hunan Children's Hospital
-
-
Jiangxi
-
Nanchang, Jiangxi, Čína, 330000
- Zatím nenabíráme
- Dermatology Hospital of Jiangxi Province
-
-
Zhejiang
-
Hangzhou, Zhejiang, Čína, 310009
- Nábor
- Hangzhou Third People's Hospital
-
-
-
-
-
Zaragoza, Španělsko, 50009
- Nábor
- Hospital Universitario Miguel Servet
-
-
A Coruña [LA Coruña]
-
Santiago de Compostela, A Coruña [LA Coruña], Španělsko, 15706
- Nábor
- CHUS - Hospital Clinico Universitario
-
-
Barcelona
-
Granollers, Barcelona, Španělsko, 08402
- Nábor
- Hospital General de Granollers
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria for the Extension Cohort:
1. Participants who have completed the treatment phase of the qualifying parent study (age 2 to <12 years old).
• No contraception methods are required for male participants. Female participants must not be pregnant or breastfeeding and, if the participant is of child-bearing potential, must use a highly effective form of contraception (i.e., abstinence) during the study intervention period and for at least 28 days after the last dose of study intervention.
Inclusion Criteria for the De Novo Cohort:
Age
-
Children aged 6 to <12 years at the time of informed consent/assent.
• No contraception methods are required for male participants.
Disease Characteristics:
-
Participants who meet all of the following AD criteria:
- A documented diagnosis of chronic AD for at least 6 months prior to screening and confirmed at screening and baseline visits according to the Hanifin and Rajka criteria; and
- A diagnosis of moderate-to-severe AD at the baseline visit (must fulfill all of the following criteria: BSA ≥10%, vIGA ≥3, EASI ≥16, and WI-NRS ≥4); and
- Documented history (within 6 months of the screening visit) of inadequate response to treatment with topical medical therapy for AD (eg, TCS and TCI), for at least 4 weeks and are candidates for systemic therapy.
Other Inclusion Criteria:
-
Body weight ≥15 kg
Exclusion Criteria for the Extension Cohort:
Medical Conditions:
-
Any medical or psychiatric condition including any active suicidal ideation in the past year or suicidal behavior in the past 5 years or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.
If the participant has SDQ total score ≥17, the investigator should exclude the child or refer them to a pediatric MHP to determine if it is safe to participate in the study. A copy or summary of the evaluation should be placed in the site source documents.
Prior/Concomitant Therapy:
-
Required use of any prohibited concomitant treatments outlined in Section 6.9.3 and Appendix 9 of study protocol.
-
Required vaccination with live attenuated vaccines during study treatment and for 6 weeks after discontinuing study treatment.
Diagnostic Assessments:
-
Ongoing adverse event in the parent studies which in the opinion of the investigator, or sponsor, is an ongoing safety concern OR the participant is currently triggering safety monitoring criteria.
-
Discontinued from treatment early in the parent studies OR triggered a discontinuation criterion at any point during the parent studies OR meets exclusion criteria from the parent studies which in the opinion of the investigator, or sponsor, is an ongoing safety concern.
Exclusion Criteria for the De Novo Cohort
Medical Conditions:
-
Any medical or psychiatric condition including any active suicidal ideation in the past year or suicidal behavior in the past 5 years or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.
If the participant has SDQ total score ≥17, the investigator should exclude them or refer the child to a pediatric MHP to determine if it is safe to participate in the study. A copy or summary of the evaluation should be placed in the site source documents.
-
Have any of the following medical conditions:
-
Infections:
- Skin infections that require treatment with systemic antimicrobials within 2 weeks prior to Day 1 (baseline) or have superficial skin infections within 1 week of Day 1.
- History of systemic infection requiring hospitalization or parenteral antimicrobial therapy or as otherwise judged clinically significant by the investigator within 1 month prior to Day 1.
- Have a history (single episode) of disseminated herpes zoster or disseminated herpes simplex, or a recurrent localized, dermatomal herpes zoster.
- Infection with HIV, hepatitis B, and/or hepatitis C
- Evidence of active TB or inadequately treated latent TB.
-
Skin Conditions:
- Including but not limited to psoriasis, seborrheic dermatitis or lupus on Day 1 that would interfere with evaluation of AD or response to treatment.
-
Other Conditions:
- Documented history of skeletal dysplasia.
- Documented history of retinal detachment.
- History of or conditions associated with thrombocytopenia, coagulopathy or platelet dysfunction.
- Prior history of leukemia, lymphoma, sarcoma or any other malignancy.
- Immunodeficiency disorder or a first-degree relative with a hereditary immunodeficiency.
- Any other medical conditions that in the investigator's judgment make the participant inappropriate for the study.
Prior/Concomitant Therapy:
-
-
Prior treatment with a systemic JAK inhibitor for AD.
-
Live attenuated vaccination within 6 weeks prior to Day 1 or require vaccination with live attenuated vaccines during treatment or within 6 weeks after the last dose of study intervention.
-
Concomitant use of strong inhibitors and inducers of CYP2C19 enzymes and strong inducers of CYP2C9 enzymes is not allowed in the study.
Prior/Concurrent Clinical Study Experience:
-
Previous administration of an investigational drug within 30 days or 5 half lives, whichever is longer, of Day 1.
Diagnostic Assessments:
-
Hepatic and/or renal and/or hematological abnormalities defined as:
- AST >2 x ULN
- Hemoglobin <10 g/dL
- ALT >2 x ULN
- ANC <1000/mm3
- Total bilirubin ≥1.5 x ULN
- ALC <500/mm3
- eGFR <60 mL/min/1.73 m2
- Platelets <150,000 /mm3
Other Exclusion Criteria:
-
Investigator site staff directly involved in the conduct of the study and their family members, site staff otherwise supervised by the investigator, and sponsor and sponsor delegate employees directly involved in the conduct of the study and their family members.
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: Nerandomizované
- Intervenční model: Přiřazení jedné skupiny
- Maskování: Žádné (otevřený štítek)
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
|---|---|
|
Experimentální: Extension
Patients who have completed other abrocitinib studies |
Abrocitinib administered as liquid oral suspension.
Ostatní jména:
|
|
Experimentální: De novo
Patients who have not participated other abrocitinib studies |
Abrocitinib administered as liquid oral suspension.
Ostatní jména:
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Number of Participants with Treatment-Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and adverse events (AEs) that lead to study discontinuation
Časové okno: 0-24 months
|
The number of the treatment emergent adverse events, serious adverse events and adverse events leading to discontinuation among patients with moderate-to-severe disease treated with abrocitinib regardless of discontinuation from study treatment. |
0-24 months
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Number of Participants With Clinically Significant Laboratory Abnormalities
Časové okno: 0-24 months
|
The number of clinically significant laboratory abnormalities among participants with moderate-to-severe disease treated with abrocitinib. |
0-24 months
|
|
Response based on achieving Validated Investigator's Global Assessment (vIGA) score of clear (0) or almost clear (1) (on a 5-point scale) and a 2 -point reduction from baseline at all scheduled time points
Časové okno: Baseline, 24 months
|
Proportion of responders based on vIGA at all scheduled time points in patients with moderate-to-severe disease treated with abrocitinib |
Baseline, 24 months
|
|
Percentage of Response based on achieving a ≥4 point improvement from baseline in the Worst Itch Numerical Rating Scale (WI-NRS) at all scheduled time points in participants aged ≥2 to <6 years
Časové okno: 0-24 months
|
Percentage of responders based on achieving an improvement ≥4 points from baseline at all scheduled time points in the WI-NRS (in patients aged ≥2 to <6 years) with moderate-to-severe disease treated with abrocitinib. |
0-24 months
|
|
Percentage of Response based on achieving a ≥4-point improvement from baseline in the WSI-NRS at all scheduled time points in participants aged ≥6 to 12 years
Časové okno: 0-24 months
|
Percentage of responders based on achieving an improvement ≥4 points from baseline at all scheduled time points in the WSI-NRS (in patients aged ≥6 to 12 years) with moderate-to-severe disease treated with abrocitinib. |
0-24 months
|
|
Percentage of Responders based on achieving Eczema Area and Severity Index (EASI)-50, EASI-90 and EASI-100 at all scheduled time points in participants with moderate-to-severe disease treated with abrocitinib
Časové okno: 0-24 months
|
Percentage of response based on achieving ≥50%, ≥90%, 100% improvement from parent study baseline in the EASI total score (EASI-50, EASI-90, EASI-100) at all scheduled time points. |
0-24 months
|
|
Percent Change from Baseline (CFB) in EASI total score at all scheduled time points.
Časové okno: 0-24 months
|
Mean percent CFB in EASI total score at all scheduled time points in patients with moderate-to-severe disease treated with abrocitinib |
0-24 months
|
|
Percentage of Participants with Flares
Časové okno: 0-24 months
|
Percentage of participants reporting flares in patients with moderate-to-severe disease treated with abrocitinib. |
0-24 months
|
|
CFB in the percentage Body Surface Area (BSA) affected at all scheduled time points
Časové okno: 0-24 months
|
Mean CFB in BSA affected at all scheduled time points in patients with moderate-to-severe disease treated with abrocitinib. |
0-24 months
|
|
CFB in Children's Dermatology Life Quality Index (CDLQI) at all scheduled time points.
Časové okno: 0-24 months
|
Mean CFB in CDLQI at all scheduled time points in participants aged ≥4 to <16 years with moderate-to-severe disease treated with abrocitinib. |
0-24 months
|
|
CFB in in Infants' Dermatitis Quality of Life (IDQOL) Index at all scheduled time points
Časové okno: 0-24 months
|
Mean CFB in IDQOL Index or CDQLI depending on age at all scheduled time points in participants aged <4 years with moderate-to-severe disease treated with abrocitinib |
0-24 months
|
|
CFB in Patient-Oriented Eczema Measure (POEM) at all scheduled time points
Časové okno: 0-24 months
|
Mean CFB in POEM at all scheduled time points in participants with moderate-to-severe disease treated with abrocitinib. |
0-24 months
|
|
CFB in Dermatitis Family Impact (DFI) at all scheduled time points
Časové okno: 0-24 months
|
Mean CFB in DFI at all scheduled time points in participants with moderate-to-severe disease treated with abrocitinib. |
0-24 months
|
|
CFB in Patient Global Impression of Severity (PGIS) at all scheduled time points
Časové okno: 0-24 months
|
Mean CFB in PGIS (in patients aged 6 to <12 years) at all scheduled time points in patients with moderate-to-severe disease treated with abrocitinib. |
0-24 months
|
|
CFB in Observer Reported Global Impression of Severity (OGIS) at all scheduled time points
Časové okno: 0-24 months
|
Mean CFB in OGIS (in patients aged 2 to <6 years) at all scheduled time points in patients with moderate-to-severe disease treated with abrocitinib |
0-24 months
|
|
CFB in the the EuroQol- 5 Dimension Youth (EQ-5D-Y)
Časové okno: 0-24 months
|
Mean CFB in EQ-5D-Y at all scheduled time points in patients with moderate-tosevere AD treated with abrocitinib versus placebo. |
0-24 months
|
|
Number of topical corticosteroid and /or topical calcineurin inhibitor free days
Časové okno: 0-24 months
|
Mean number of days free from topical corticosteroids and /or topical calcineurin inhibitor use in patients with moderate-to-severe disease treated with abrocitinib. |
0-24 months
|
|
Percentage of Participants Achieving satisfactory response in Tdap/DTaP and/or pneumococcal antibody titers as appropriate in participants who receive Tdap/DTaP and/or pneumococcal vaccinations
Časové okno: 0-24 months
|
For patients that receive Tdap/ DTap and/or pneumococcal vaccinations during the study, the proportion of patients treated with abrocitinib who achieve satisfactory immunogenicity at 4 weeks after receiving the vaccinations. |
0-24 months
|
Spolupracovníci a vyšetřovatelé
Sponzor
Vyšetřovatelé
- Ředitel studie: Pfizer CT.gov Call Center, Pfizer
Publikace a užitečné odkazy
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Primární dokončení (Odhadovaný)
Dokončení studie (Odhadovaný)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
- Genetické choroby, vrozené
- Onemocnění imunitního systému
- Přecitlivělost, okamžitá
- Přecitlivělost
- Kožní choroby
- Kožní onemocnění, genetické
- Kožní onemocnění, ekzematózní
- Dermatitida
- Vrozené, dědičné a neonatální nemoci a abnormality
- Onemocnění kůže a pojivové tkáně
- Dermatitida, atopika
- Ekzém
- Abrocitinib
Další identifikační čísla studie
- B7451031
- 2023-509124-18-00 (Identifikátor registru: CTIS (EU))
- 2023 (Grant/smlouva NIH USA)
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Popis plánu IPD
Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .